20 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
and regulations may restrict or prohibit a wide range of pricing, discounting, labeling, marketing and promotion, sales commission, customer incentive
S-1/A
EX-1.1
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
, drawings, specifications, research records, records of inventions, test information, financial, marketing and business data, customer and supplier lists
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained
S-1
kw601grpfrpw72
25 Aug 23
IPO registration
5:03pm
S-1
EX-2.2
k2vu8uj
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.3
bz8tq
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.19
avrhw hus7vk1hvu
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.4
owd8pno
25 Aug 23
IPO registration
5:03pm
DRS/A
uvuxfhbrs9qy
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
EX-10.20
8jrp76080xl0gel
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
nzfso
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
mos6a796r
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
woa1e113obnxnboheuh
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
hcsukd32 nu
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
smni078 q65zlim52t
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
EX-10.6
t60dl6ud2 0cn25fb
23 Dec 21
Draft registration statement (amended)
12:00am
DRS/A
y06aldav nn
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
xpnk4
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next